Nanexa AB NANEXA

The Danish drugmaker signed a licensing deal for a weight-loss treatment being developed by Hengrui Pharma that could be worth up to $2.6 billion.

It was reported on September 25 that Novo Nordisk A/S (NYSE:NVO) has entered into an exclusive global license and collaboration agreement with Swedish drug delivery platform company Nanexa AB. The partnership centers on leveraging Nanexa’s proprietary PharmaShell technology platform across up to five development programs focused on obesity, type 2 diabetes, and other cardiometabolic indications. […]

Novo has meanwhile been busy bolstering its pipeline amid a target to launch more than five multi-blockbusters by 2030.

Novo Nordisk (CPSE:NOVO B) agreed a €1.165b global licensing deal with Swedish drug delivery specialist Nanexa for long-acting injectables. The collaboration targets obesity, type 2 diabetes, and wider cardiometabolic conditions using Nanexa's PharmaShell depot technology to extend dosing intervals. Novo Nordisk gains exclusive rights to apply PharmaShell across selected pipeline assets, with Nanexa eligible for upfront, milestone, and royalty payments. The Nanexa PharmaShell licensing deal...

Big pharma is still paying up, but more often for delivery and discovery engines than for a single late-stage asset.

European stock markets closed mostly higher in Friday trading as oil prices fell amid hopes of a pos

The collaboration covers up to five programs in obesity, diabetes and other cardiometabolic diseases.

Nanexa's shares more than doubled

The agreement gives Novo exclusive rights to Swedish startup Nanexa's drug-coating technology for up to 5 programs targeting obesity and diabetes

Novo’s latest alliance involves injectables given every one to three months. Elsewhere, Nektar won a legal spat with Eli Lilly and the FDA issued two approvals.

Nanexa AB (publ) ("Nanexa"), a Swedish drug delivery platform company developing long-acting injectable drugs based on its proprietary PharmaShell® technology platform, today announces that it has entered into a global exclusive license and collaboration agreement with Novo Nordisk ("Novo") for the use of the PharmaShell® technology platform for certain peptide-based drugs targeting obesity, type 2 diabetes and other cardiometabolic indications.

Novo Nordisk (NYSE:NVO) has agreed to license drug-delivery technology from Swedish biotechnology company Nanexa in an agreement potentially worth up to €1. 165 billion.

Investing.com -- Shares of Nanexa surged more than 110% in early Friday trading after the Swedish drug-delivery company announced a global licensing and collaboration agreement with Novo Nordisk worth up to €1.165 billion ($1.3 billion), covering technology aimed at making obesity and diabetes treatments longer-lasting.

Novo Nordisk A/S signed a deal worth as much as €1.165 billion ($1.3 billion) with Sweden’s Nanexa AB, the latest in a string of small acquisitions as the Danish company tries to ensure it can grow through a looming patent cliff.

Collaboration intended to develop large-scale, GMP-compliant ALD manufacturing equipment supporting Nanexa’s broad portfolio of proprietary and partnered PharmaShell® programs. DENVER and UPPSALA, Sweden, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Forge Nano, Inc., a leading U.S.-based semiconductor equipment and advanced materials company pioneering Atomic Layer Deposition (“ALD”) technology for artificial intelligence (“AI”)-era chip manufacturing and defense battery applications, which has signed an

As the European market navigates through a period of cautious optimism, with central banks maintaining interest rates amid geopolitical uncertainties, investors are keenly observing sectors for potential opportunities. Penny stocks, often associated with smaller or newer companies, continue to present intriguing possibilities by offering both affordability and growth potential when supported by strong financials. This article will explore several penny stocks that stand out for their...